CL2021001934A1 - Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar. - Google Patents
Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar.Info
- Publication number
- CL2021001934A1 CL2021001934A1 CL2021001934A CL2021001934A CL2021001934A1 CL 2021001934 A1 CL2021001934 A1 CL 2021001934A1 CL 2021001934 A CL2021001934 A CL 2021001934A CL 2021001934 A CL2021001934 A CL 2021001934A CL 2021001934 A1 CL2021001934 A1 CL 2021001934A1
- Authority
- CL
- Chile
- Prior art keywords
- bile acid
- compounds
- acid modulators
- diseases
- benzothiadiazepine
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 3
- 239000003613 bile acid Substances 0.000 title abstract 3
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical class S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 abstract 2
- 108091006614 SLC10A2 Proteins 0.000 abstract 2
- CICPSCXBPAGDJY-UHFFFAOYSA-N 1,2,5-benzothiadiazepine Chemical class S1N=CC=NC2=CC=CC=C12 CICPSCXBPAGDJY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a los derivados 1,2,5 de benzotiadiazepina de la fórmula (I). Estos compuestos son moduladores del ácido biliar que tienen el transportador apical del ácido biliar dependiente del sodio (ASBT) y/o actividad inhibidora del transporte del ácido biliar del hígado (LBAT). La invención también se refiere a las composiciones farmacéuticas que comprenden estos compuestos y con el uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, metabolismo del ácido graso y trastornos debido al uso de la glucosa, enfermedades gastrointestinales y enfermedades hepáticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911004690 | 2019-02-06 | ||
| SE1950464 | 2019-04-12 | ||
| IN201911049981 | 2019-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001934A1 true CL2021001934A1 (es) | 2022-04-01 |
Family
ID=69591608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001934A CL2021001934A1 (es) | 2019-02-06 | 2021-07-22 | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230406832A1 (es) |
| EP (1) | EP3921028B1 (es) |
| JP (1) | JP2022519370A (es) |
| KR (1) | KR20210126053A (es) |
| CN (1) | CN113677398A (es) |
| AU (1) | AU2020218908A1 (es) |
| BR (1) | BR112021015060A2 (es) |
| CA (1) | CA3127568A1 (es) |
| CL (1) | CL2021001934A1 (es) |
| CO (1) | CO2021010400A2 (es) |
| CR (1) | CR20210458A (es) |
| DK (1) | DK3921028T3 (es) |
| EC (1) | ECSP21056710A (es) |
| ES (1) | ES2937153T3 (es) |
| FI (1) | FI3921028T3 (es) |
| HR (1) | HRP20230039T1 (es) |
| HU (1) | HUE060905T2 (es) |
| IL (1) | IL284983B1 (es) |
| LT (1) | LT3921028T (es) |
| MX (1) | MX2021008981A (es) |
| PE (1) | PE20212251A1 (es) |
| PL (1) | PL3921028T3 (es) |
| PT (1) | PT3921028T (es) |
| RS (1) | RS63899B1 (es) |
| SG (1) | SG11202108566VA (es) |
| SI (1) | SI3921028T1 (es) |
| TW (1) | TW202045483A (es) |
| UA (1) | UA127911C2 (es) |
| WO (1) | WO2020161217A1 (es) |
| ZA (1) | ZA202106472B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| WO2019234077A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| PE20210182A1 (es) | 2018-06-20 | 2021-01-29 | Albireo Ab | Modificaciones de cristales de odexibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| KR20220109450A (ko) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| CN114761080A (zh) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761018A (zh) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| TW202134218A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
| TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59108326D1 (de) | 1990-12-06 | 1996-12-12 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel |
| FI108451B (fi) | 1991-12-20 | 2002-01-31 | Hoechst Ag | Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| DK0573848T3 (da) | 1992-06-12 | 1998-08-10 | Hoechst Ag | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler |
| IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| TW289020B (es) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| TW289757B (es) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| TW289021B (es) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| AU700557B2 (en) | 1994-09-13 | 1999-01-07 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| CN1110494C (zh) | 1996-03-11 | 2003-06-04 | G·D·瑟尔公司 | 具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因 |
| ATE197842T1 (de) | 1996-07-24 | 2000-12-15 | Zumtobel Staff Gmbh | Adapter für ein haltemittel, welches zum befestigen einer einbauleuchte in einer einbauöffnung bestimmt ist, oder haltemittel oder einbauleuchte mit einem solchen adapter |
| DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
| GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| NZ337830A (en) | 1997-03-11 | 2001-07-27 | G | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| EP0864582B1 (en) | 1997-03-14 | 2003-06-04 | Aventis Pharma Deutschland GmbH | Hypolipidemic 1,4-benzothiazepine-1,-dioxides |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| NZ512532A (en) | 1998-12-23 | 2003-12-19 | G | Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis |
| CN1338945A (zh) | 1998-12-23 | 2002-03-06 | G·D·瑟尔有限公司 | 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合 |
| AU776952B2 (en) | 1998-12-23 | 2004-09-30 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| CZ20012342A3 (cs) | 1998-12-23 | 2001-12-12 | G. D. Searle Llc | Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny fibrové pro kardiovaskulární indikace |
| HUP0201972A3 (en) | 1998-12-23 | 2005-06-28 | G D Searle Llc Chicago | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| HUP0105409A3 (en) | 1999-02-12 | 2004-11-29 | G D Searle Llc Chicago | 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| ATE349214T1 (de) | 2001-09-08 | 2007-01-15 | Astrazeneca Ab | Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| ATE531701T1 (de) | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
| DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
| KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
| CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
| WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
-
2020
- 2020-02-06 MX MX2021008981A patent/MX2021008981A/es unknown
- 2020-02-06 WO PCT/EP2020/052942 patent/WO2020161217A1/en unknown
- 2020-02-06 SI SI202030140T patent/SI3921028T1/sl unknown
- 2020-02-06 CR CR20210458A patent/CR20210458A/es unknown
- 2020-02-06 PE PE2021001268A patent/PE20212251A1/es unknown
- 2020-02-06 JP JP2021545897A patent/JP2022519370A/ja active Pending
- 2020-02-06 TW TW109103758A patent/TW202045483A/zh unknown
- 2020-02-06 PT PT207053059T patent/PT3921028T/pt unknown
- 2020-02-06 HU HUE20705305A patent/HUE060905T2/hu unknown
- 2020-02-06 KR KR1020217028378A patent/KR20210126053A/ko active Search and Examination
- 2020-02-06 IL IL284983A patent/IL284983B1/en unknown
- 2020-02-06 EP EP20705305.9A patent/EP3921028B1/en active Active
- 2020-02-06 CA CA3127568A patent/CA3127568A1/en active Pending
- 2020-02-06 ES ES20705305T patent/ES2937153T3/es active Active
- 2020-02-06 PL PL20705305.9T patent/PL3921028T3/pl unknown
- 2020-02-06 HR HRP20230039TT patent/HRP20230039T1/hr unknown
- 2020-02-06 AU AU2020218908A patent/AU2020218908A1/en active Pending
- 2020-02-06 RS RS20230040A patent/RS63899B1/sr unknown
- 2020-02-06 LT LTEPPCT/EP2020/052942T patent/LT3921028T/lt unknown
- 2020-02-06 SG SG11202108566VA patent/SG11202108566VA/en unknown
- 2020-02-06 UA UAA202104946A patent/UA127911C2/uk unknown
- 2020-02-06 DK DK20705305.9T patent/DK3921028T3/da active
- 2020-02-06 FI FIEP20705305.9T patent/FI3921028T3/fi active
- 2020-02-06 BR BR112021015060-9A patent/BR112021015060A2/pt unknown
- 2020-02-06 CN CN202080012140.4A patent/CN113677398A/zh active Pending
-
2021
- 2021-07-22 CL CL2021001934A patent/CL2021001934A1/es unknown
- 2021-07-30 EC ECSENADI202156710A patent/ECSP21056710A/es unknown
- 2021-08-06 CO CONC2021/0010400A patent/CO2021010400A2/es unknown
- 2021-09-03 ZA ZA2021/06472A patent/ZA202106472B/en unknown
-
2023
- 2023-02-03 US US18/164,185 patent/US20230406832A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3127568A1 (en) | 2020-08-13 |
| CN113677398A (zh) | 2021-11-19 |
| IL284983B1 (en) | 2024-03-01 |
| HRP20230039T1 (hr) | 2023-06-09 |
| DK3921028T3 (da) | 2023-01-23 |
| MX2021008981A (es) | 2021-09-08 |
| AU2020218908A1 (en) | 2021-08-26 |
| IL284983A (en) | 2021-09-30 |
| BR112021015060A2 (pt) | 2021-10-05 |
| WO2020161217A1 (en) | 2020-08-13 |
| SI3921028T1 (sl) | 2023-02-28 |
| US20230406832A1 (en) | 2023-12-21 |
| ECSP21056710A (es) | 2021-08-31 |
| FI3921028T3 (fi) | 2023-01-31 |
| JP2022519370A (ja) | 2022-03-23 |
| CR20210458A (es) | 2021-11-04 |
| ZA202106472B (en) | 2023-04-26 |
| HUE060905T2 (hu) | 2023-04-28 |
| EP3921028B1 (en) | 2022-11-09 |
| ES2937153T3 (es) | 2023-03-24 |
| EP3921028A1 (en) | 2021-12-15 |
| CO2021010400A2 (es) | 2021-08-19 |
| PL3921028T3 (pl) | 2023-02-13 |
| PE20212251A1 (es) | 2021-11-24 |
| LT3921028T (lt) | 2023-02-10 |
| TW202045483A (zh) | 2020-12-16 |
| RS63899B1 (sr) | 2023-02-28 |
| UA127911C2 (uk) | 2024-02-07 |
| KR20210126053A (ko) | 2021-10-19 |
| PT3921028T (pt) | 2023-02-15 |
| SG11202108566VA (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001934A1 (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar. | |
| CO2022007172A2 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar | |
| ECSP22040834A (es) | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar | |
| CO2023016072A2 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| AR120676A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
| AR120683A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
| ECSP11011324A (es) | 3h-imidazo[4,5-c]piridina-6-carboxamidas en calidad de agentes antiinflamatorios | |
| AR120682A1 (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar | |
| CR20210201A (es) | Nuevos compuestos antihelmínticos | |
| CO6351742A2 (es) | Compuestos organicos para la cicatrizacion de heridas | |
| CR10192A (es) | Compuestos de amido y su uso como productos farmaceuticos | |
| EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| UY27846A1 (es) | Compuestos quimicos | |
| BRPI1007379B8 (pt) | composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli | |
| BR112023010799A2 (pt) | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares | |
| AR120674A1 (es) | Compuestos de benzotiazepina y su uso como ácido biliar | |
| EA201170190A1 (ru) | Фармацевтическая композиция, содержащая экстракт мозга свиньи | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| CL2010001566A1 (es) | Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune. | |
| CO2021000229A2 (es) | Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma | |
| UY29640A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos. | |
| NI201200196A (es) | Agentes terapéuticos 976 | |
| CO2021004612A2 (es) | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento | |
| EA201200028A1 (ru) | Альфа-1 мультимеры hla-g и их фармацевтическое применение |